Mannose modified co-loaded zoledronic liposomes deplete M2-tumor-associated macrophages to enhance anti-tumor effect of doxorubicin on TNBC

As the most numerous inflammatory cell group in tumor microenvironment, tumor-associated macrophages (TAMs) have an essential effect therapy and are potential therapeutic targets. M2 type (M2-TAMs) were involved entire process of development, invasion, metastasis, obstructing anti-tumor chemotherapy drugs nano-medicine. This study aimed to construct a mannose modified co-loaded zoledronic acid doxorubicin liposomes ([email protected]/DOX) for improving by suppressing M2-TAMs on triple-negative breast cancer (TNBC). The size, PDI, Zeta-potential [email protected]/DOX determined be 212.80 ± 7.74 nm, 0.1413 0.0232, −33.63 0.49 mV, respectively. protected]/DOX's EE% DL% ZOL as measured 17.21 2.26% 1.56 0.21%, while DOX, they 84.42 2.05% 5.12 0.14%. uptake Man-LP into cells was increased when it with TAMs target ligand. inhibited invasion MDA-MB-231 induced M2-TAMs, expression biomarkers (Arg1 CD206 vitro, CD68, vivo) apparent. Moreover, liposome system remarkably enhanced anticancer effects both vitro vivo combined ZOL. In conclusion, all these results established that could enhance DOX via depleting TNBC.